Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 20881619.
- Also identified by DOI 10.1097/JOM.0b013e3181f73ae6.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine the frequency of "signature" chromosomal abnormalities in oncology workers handling anticancer drugs. Peripheral blood from health care personnel (N = 109) was examined with probes for targets on chromosomes 5, 7, and 11. The effect of drug-handling frequency on chromosome abnormalities was assessed. An excess of structural (0.18 vs 0.02; P = 0.04) and total abnormalities (0.29 vs 0.04; P = 0.01) of chromosome 5 was observed in the high-exposure group compared with the unexposed. Increased incidence rate ratios (IRRs) for abnormalities of chromosome 5 (IRR = 1.24; P = 0.01) and for either chromosome 5 or 7 (IRR = 1.20; P = 0.01) were obtained at 100 handling events. Effect sizes were augmented 2- to 4-fold when alkylating agent handling alone was considered. Biologically important exposure to genotoxic drugs is apparently occurring in oncology work settings despite reported use of safety practices.
Medical subject headings
- Antineoplastic Agents
- Chromosome Aberrations
- Chromosomes, Human, Pair 5
- Chromosomes, Human, Pair 7
- Medical Oncology
- Polymorphism, Genetic